

1 **Validation of the Kinetik Blood Pressure Monitor – Series 1 for use in adults at home and in clinical**
2 **settings, according to the 2002 European Society of Hypertension International Protocol on the**
3 **validation of blood pressure devices**

4

5 Schwartz CL¹, Edwards K², Gamble W², Kirkham A², Lacy P³, Lewis P⁴, McDonagh STJ⁵, Peers C²,
6 Sheppard JP¹, Swales P², Howarth J,⁶ Williams B³

7 ¹ *Nuffield Department of Primary Care Health Sciences, NIHR School for Primary Care Research,*
8 *University of Oxford, Radcliffe Observatory Quarter, Oxford OX2 6GG, UK;*

9 ² *University Hospitals of Leicester, Glenfield Hospital, Leicester LE3 9QP*

10 ³ *Institute of Cardiovascular Sciences, NIHR UCL Hospitals Biomedical Research Centre, University*
11 *College London, 170 Tottenham Court Road, London, W1T 7HA, UK*

12 ⁴ *Stockport NHS Foundation Trust, Stepping Hill Hospital, Stockport, SK2 7JE*

13 ⁵ *Primary Care Research Group, University of Exeter Medical*

14 *School, College of Medicine and Health, Smeall Building, St Luke's Campus, Exeter, UK*

15 ⁶ *British and Irish Hypertension Society, UK*

16

17 **Correspondence to:**

18 Dr James Sheppard email: james.sheppard@phc.ox.ac.uk

19 **Abstract**

20 The aim of this study was to assess the blood pressure (BP) measurement accuracy of the Kinetik
21 Blood Pressure Monitor – Series 1 (BPM-1) for use in home or clinical settings according to the 2002
22 European Society of Hypertension International Protocol (ESH-IP). Forty-two participants were
23 recruited to fulfil the required number of systolic and diastolic BP measurements according to the
24 ESH-IP. Nine sequential same-arm BP readings were measured and analysed for each participant
25 using the test device and observer mercury standard readings according to the 2002 ESH-IP. The 41
26 participants were used to obtain 33 sets of systolic and diastolic BP readings and were included in
27 the analysis. Mean difference between the device measurements and the observer (mercury
28 standard) measurements was $1.1 \pm 7.2 / 1.1 \pm 6.8$ mmHg (mean \pm standard deviation; systolic/diastolic).
29 The number of systolic BP differences between the test and observer measurements that fell within
30 5, 10 and 15 mmHg was 65, 86 and 92. For diastolic readings, the number of test - observer
31 measurement differences within 5, 10 and 15 mmHg was 77, 91 and 94. The number of participants
32 with at least two out of three differences within 5 mmHg was 28 for systolic and 40 for diastolic BP
33 readings. Three participants had no differences between the test and observer measurements within
34 5 mmHg in both the systolic and diastolic measurement categories. The Kinetik BPM series 1 device
35 fulfilled the requirements of the ESH-IP validation procedure and can be recommended for clinical
36 use and self-measurement within the home.

37 **Abstract word count: 247**

38 **What is known about this topic**

- 39 • Clinical validation of blood pressure monitors is important to ensure they are accurate for
40 use at home and in routine clinical practice.
- 41 • The consistency of the validation process is ensured by the use of standardised protocols
42 such as that developed by the European Society of Hypertension in 2002.

43 **What this study adds**

- 44 • The present study examined the accuracy of the Kinetik BPM series 1 electronic monitor
45 using the European Society of Hypertension International protocol.
- 46 • In 41 subjects, the mean blood pressure difference between the device measurements and
47 the observer (mercury standard) measurements was $1.1 \pm 7.2 / 1.1 \pm 6.8$ mmHg (mean \pm
48 standard deviation; systolic/diastolic). In a total of 99 measurements, the number of systolic
49 differences that fell within 5, 10 and 15 mmHg was 65, 86 and 92.
- 50 The Kinetik BPM series 1 device fulfilled all of the requirements of the ESH-IP validation
51 procedure and can be recommended for clinical use and self-measurement within the home.

52 **Introduction**

53 The Kinetik BPM series 1 electronic monitor is a simple, automatic, lightweight, portable monitor
54 that was developed to be an accurate and affordable method of measuring blood pressure (BP). The
55 device is intended for home use by adults and in clinical settings by health professionals. The
56 popularity of patients self-monitoring their BP is increasing,⁽¹⁾ particularly as self-monitoring can lead
57 to more effective BP control.⁽²⁾ Due to ease of use and portability, electronic BP monitor usage has
58 also increased within general practice.⁽³⁾ It is important that health professionals and patients have
59 confidence in the accuracy of the BP measurements. A monitor that has been independently
60 validated against a well-established set of criteria is a vital factor when considering, or
61 recommending, a monitor to purchase. The aim of this study was to assess the BP measurement
62 accuracy of the device in adults using the European Society of Hypertension International Protocol
63 (ESH-IP) for the validation of BP measuring devices in adults from 2002.⁽⁴⁾

64 **Participants and Methods**

65 *Test Device*

66 The Kinetik BPM series 1 (produced by Kinetik Medical Devices Ltd, Elstree, Herts, UK) is an
67 automated, electronic, digital, upper arm BP monitor. The device operates using the oscillometric⁽⁵⁾
68 method and is designed for use at home and in clinical practice. It is powered by four AAA batteries
69 or an external 6V, 600mA DC adapter (not included as standard). The device has a BP measurement
70 range of 0 to 300 mmHg and a heart rate detection range of 40 to 180 beats per minute. The
71 measuring accuracy is stated to be within ± 3 mmHg for BP and within ± 5 % for heart rate. The
72 device, which has memory capacity for 60 sets of BP readings, comes with three cuff sizes; a
73 standard cuff, supplied with the monitor (22 – 30 cm arm circumference), a large cuff (30 – 42 cm
74 arm circumference) and an extra-large cuff (42 – 48 cm arm circumference). The manufacturer
75 states that periodic re-calibration is not required if the BP monitor is used according to instructions.
76 The manufacturer provided three samples of the monitor and all three sizes of cuff to test.

77 *Recruitment and Participant Selection*

78 At least 33 participants are needed to fulfil the BP monitor validation requirements, 15 for phase 1
79 and a total of 33 for phase 2. Forty-two participant and staff volunteers were recruited from the
80 outpatient hypertension clinic at Glenfield Hospital, Leicester, UK. As specified by the ESH-IP, all
81 participants were over the age of 30 years and special groups, such as pregnant women, were not
82 included.⁽⁴⁾ Written, informed consent was obtained from all study participants. Twenty-one were
83 recruited for phase 1, based on inclusion of five systolic and five diastolic readings for each BP
84 category (low, medium and high), and at least five male and five female subjects across the BP
85 categories. Participants had their arm circumference recorded to ensure that the appropriate cuff
86 (standard, large or extra-large) was used according to the participant's measurement. This was not
87 needed for the selection process as the ESH-IP assumes that there will be a representative spread
88 based on the BP selection criteria.⁽⁴⁾ An additional 20 participants were recruited for phase 2 to
89 achieve the required 11 systolic and 11 diastolic BP readings in each BP category (low, medium and
90 high).

91 *Procedure*

92 The study was conducted in one of the consulting rooms in the Glenfield Hospital, Leicester, UK, by
93 an experienced supervisor and member of the British Hypertension Society (BHS) Blood Pressure
94 Measurement Working Party, and three trained observers, overseen by a principal investigator.
95 Observers were fully trained in accurate BP measurement according to the test requirements of the
96 BHS DVD specified in the ESH-IP⁽⁴⁾ and were familiarised with the device prior to the study.
97 Participants were instructed not to eat, smoke or drink caffeinated drinks or alcohol for one hour
98 before the first BP measurement. The participant was seated comfortably for 10 minutes prior to BP
99 measurement. The participant's arm was supported and the cuff placed at heart level whilst the BP
100 measurement was taken; talking and moving was avoided.

101 *Reference BP*

102

103 One cuff was connected to two mercury sphygmomanometers via a Y-tube connector (calibrated
104 before the study initiation) and this was used for simultaneous, reference auscultatory BP
105 measurements by two observers using the manual and then the test BP monitor cuff. The observers
106 were blinded from each other's readings and there had to be agreement between the readings
107 within +/- 4 mmHg. The appropriate cuff was used for each participant to ensure that the bladder
108 covered at least 80 % of their arm circumference but not more than 100 %.

109

110 *Test BP*

111

112 Nine sequential same arm measurements were taken at 30-60 s intervals using the test monitor and
113 the standard mercury device, with separate cuffs. The appropriate cuff size was used for each
114 participant following measurement of arm circumference. Two initial BP readings were taken, one
115 with the reference standard to determine the systolic and diastolic BP category for the participant
116 (high, medium or low) and the other taken with the test device. This was followed by seven BP
117 measurements, alternating the mercury standard (BP1, BP3, BP5 and BP7) with the test device (BP2,
118 BP4 and BP6).

119 *Analysis*

120 The analysis was carried out as specified in the 2002 ESH-IP⁽⁴⁾. Each test BP measurement (BP2, BP4,
121 and BP6) was paired with the mercury reference reading (BP1, BP3, BP5 and BP7) taken immediately
122 before and immediately after. The measurements with the smaller absolute difference (device -
123 mercury BP) were used for analysis (or, if the difference was equal, the first of the mercury reference
124 values was used). The BP differences were then categorised as within 5 mmHg, 10 mmHg or 15
125 mmHg. This was performed separately for systolic and diastolic BP values. The criteria for the device
126 passing the validation was based on two phases: Phase 2.1 representing the absolute number of

127 comparisons falling between 5, 10 and 15 mmHg for the 33 participants (99 comparisons) and Phase
128 2.2 representing the number of comparisons per participant which fell within 5 mmHg.

129

130 **Results**

131 *Participants*

132 Forty-two participants were recruited of whom 41 were needed to fulfil the required number of
133 systolic and diastolic BP readings for analysis. One recruited participant's data was in excess of
134 requirements and therefore not included in the analysis. Participants' characteristics are presented
135 in Table 1. Requirements in the protocol for gender, age and BP ranges were fulfilled.

136 *Validation*

137 As per the ESH-IP, phase 1 validation was carried out on 15 participants, 5 in each BP category.⁽⁴⁾ The
138 Kinetik BPM series 1 device successfully passed the requirements for this phase for both systolic and
139 diastolic BP (Table 2) and, therefore, validation continued to the second phase. Standardised Bland-
140 Altman plots are presented in Figures 1 and 2 and display the differences in BP between the device
141 and the observer (mercury standard) for phase 2 measurements. Paired comparisons for mean
142 device BP readings and mean observer BP readings in each BP category are shown in Table 3.
143 Overall, the device-observer difference was $1.1 \pm 7.2/1.1 \pm 6.8$ mmHg in the phase 2 participants (n =
144 33). The validation analysis, based on classifying the differences between the BP measurements
145 from the tested device and the measurements from the mercury standard, fulfilled the requirements
146 to pass parts 2.1 and 2.2 of the phase 2 analysis (Table 4).

147 **Discussion**

148 The Kinetik BPM series 1 electronic monitor has been tested using the 2002 ESH-IP validation
149 protocol. The device tends to overestimate low systolic BP and underestimate high systolic BP
150 relative to measurements obtained using a mercury standard. On two occasions, the monitor failed

151 to give a measurement, both of which involved different subjects with systolic pressures in the
152 “high” BP category. The monitor is more accurate at determining diastolic BP.

153 The device was able to meet the minimum criteria required for passing the validation test for systolic
154 and diastolic BP (phase 2.1 and 2.2). Therefore, the device can be recommended for home and
155 clinical use.

156 The “standard” cuff size (22-30 cm) used with this monitor is smaller than specified for many
157 automated BP devices (22-32 cm) and may account for reports from some study subjects that
158 repeated measurements were uncomfortable due to the tightness of the cuff, particularly at high BP
159 levels. The discrepancy in cuff size may result in an inappropriate cuff being used for some subjects
160 by operators not fully familiar with the cuff size range specified for this device.

161

162 **Acknowledgements**

163 The British and Irish Hypertension Society, Blood Pressure Measurement Working Party

164

165 **Conflicts of Interest**

166 **Funding**

167 **Future Legends**

168 *Table 1 – Characteristics of the included participants, BP – blood pressure, * In order to get the*
169 *required number of systolic and diastolic BP readings for the low, medium and high categories 21*
170 *participants were included overall.*

171 *Table 2 – Validation results for phase 1. Device passed therefore phase 2 validation recommended.*
172 *SBP – systolic blood pressure, DBP – diastolic blood pressure.*

173 *Table 3 – Paired comparisons between the device and mercury/observer systolic and diastolic blood*
174 *pressure for each blood pressure diagnostic group, BP – blood pressure.*

175 *Table 4 – Validation results for Phase 2. Completion of analysis produces differences between test*
176 *and observer measurements for all 33 participants in phase 2 (99 in total). Part 1 requires the*
177 *number of these comparisons that fall within 5, 10 and 15 mmHg to be determined. The comparisons*
178 *are then analysed per subject to determine the number that fall within 5 mmHg. The Kinetik BPM1*
179 *device passed both parts 1 and 2. SBP – Systolic blood pressure and DBP – Diastolic blood pressure.*


180

181 *Figure 1 – Bland-Altman plot showing the difference between the observer (mercury) systolic BP and*
182 *the device systolic BP against the mean value*

183 *Figure 2 - Bland-Altman plot showing the difference between the observer (mercury) diastolic BP and*
184 *the device diastolic BP against the mean value.*

185 **References**

- 186 1. McManus RJ, Wood S, Bray EP, Glasziou P, Hayen A, Heneghan C *et al.* Self-monitoring in
187 hypertension: a web-based survey of primary care physicians. *Journal of human hypertension.*
188 2014;28(2):123-7.
- 189 2. Tucker KL, Sheppard JP, Stevens R, Bosworth HB, Bove A, Bray EP *et al.* Self-monitoring of
190 blood pressure in hypertension: A systematic review and individual patient data meta-analysis. *PLoS*
191 *medicine.* 2017;14(9):e1002389.
- 192 3. Medicines, Healthcare Products Regulatory A. Blood Pressure Measurement Devices
193 London: Medicines and Healthcare Products Regulatory Agency 2013 [Available from:
194 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/403448/Blood_pressure_measurement_devices.pdf)
195 [/403448/Blood_pressure_measurement_devices.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/403448/Blood_pressure_measurement_devices.pdf).
- 196 4. O'Brien E, Pickering T, Asmar C, Myers M, Parati G, Staessen J *et al.* Working Group on Blood
197 Pressure Monitoring of the European Society of Hypertension International Protocol for validation of
198 blood pressure measuring devices in adults. *Blood Press Monit.* 2002;7(1):3-17.
- 199 5. Lewis PS, Chapman N, Chowienczyk P, Clark C, Denver E, Lacy P *et al.* on behalf of the British
200 and Irish Hypertension Society's Blood Pressure Measurement Working Party [Oscillometric](#)
201 [measurement of blood pressure: a simplified explanation. A technical note on behalf of the British](#)
202 [and Irish Hypertension Society.](#) *Journal of Human Hypertension* **volume 33**, pages 349–351(2019)



	Phase 1 participants (n=21)*	Phase 2 participants (n=41)
Age, Mean (SD), years	53.6 (13.1)	54.0 (11.6)
Range, years	30 - 80	30 - 80
Men, No. (%)	11 (52.4)	21 (51.2)
Arm Circumference, Mean (SD), cm (N=40)	28.2 (3.8)	30.6 (5.8)
Range, cm	23 - 36	23 - 54
Recruitment Systolic BP, Mean (SD), mmHg	143.6 (29.2)	147.7 (28.4)
Range, mmHg	99 - 199	99 - 199
Recruitment Diastolic BP, Mean (SD), mmHg	90.0 (17.4)	89.8 (16.3)
Range, mmHg	58 - 122	58 - 122
Participants in each recruitment range		
Systolic BP Low (<130)	5	11
Medium (130–160)	5	11
High (>160)	5	11
Diastolic BP Low (<80)	5	11
Medium (80–100)	5	11
High (>100)	5	11

	Within 5 mmHg	Within 10 mmHg	Within 15 mmHg
SBP	28	38	41
DBP	40	44	44
Required to pass Validation	25	5	40

Systolic BP				
Group	Mercury	Kinetik	Difference	Number
Low	113	118	5	33
Medium	140.9	141.7	0.76	33
High	161.1	158.6	-2.5	32
Diastolic BP				
Group	Mercury	Kinetik	Difference	Number
Low	71	74.1	3.1	32
Medium	87.5	87.5	0	33
High	110.6	110.7	0.1	32
			Difference - Device - Mercury mean (SD)	Number
		Systolic	1.1 (7.12)	33
		Diastolic	1.1 (6.77)	33

Part 1				
	Within 5 mmHg	Within 10 mmHg	Within 15 mmHg	Validation Result
<i>Two required</i>	65	80	95	
<i>All r required</i>	60	75	90	
Achieved				
SBP	65	86	92	Pass
DBP	77	91	94	Pass
Part 2				
<i>Diff' within 5mmHg</i>	"at least 2/3"	"none"		
<i>Required</i>	≥ 22	≤ 3		
Achieved				
SBP	22	3		Pass
DBP	27	3		Pass